Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03455478 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Shanghai Eye Study for Adults

Study acronym: SESA
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Nov 30, 2018 to Nov 30, 2019
    • Study completion date: Jul 31, 2019 to Nov 30, 2026
    • Eligibility criteria revised
    • Study title shortened, about 1 word
    v3
  2. Primary completion date: Jun 30, 2018 to Nov 30, 2018
    • Study completion date: Dec 31, 2018 to Jul 31, 2019
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Blindness and visual impairment severely impact the visual health and life quality of people, particularly the 2.566 million senior citizens aged at 65 and above in Shanghai. The main reason is uncorrected refractive error, of which, 62.1% can be solved through refractive correction. For this reason, the uncorrected refractive errors of 154,000 senior citizens in Shanghai can be taken as a priority among the public health issues to prevent blindness. Now, with the aim to reduce the prevalence rate of blindness and visual impairment, it is planned to establish a public health service mechanism in terms of refractive error screening and correction for the elderly by relying on Shanghai's three-level (city-district-community) eye diseases prevention network, using proper refractive correction technology, and moving related services forward to communities in order to screen, identity, and correct blindness and visual impairment caused by refractive errors as early as possible.
Trial Details
NCT Number NCT03455478
Lead Sponsor Shanghai Eye Disease Prevention and Treatment Center
Collaborators: Brien Holden Vision
Conditions
(from sponsor)		 Blindness,Visual Impairment, Refractive Error, Cataract, High Myopia, Aging
Related terms Blindness, Cataract, Refractive Errors, Vision Disorders
Enrollment 1,000,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov